Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07353931 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
A Phase 3 study of Osteoarthritis and Overweight or Obesity, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT07353931 is a Phase 3 study of Osteoarthritis and Overweight or Obesity that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 900 participants, above the 811-participant average among 135 other Osteoarthritis trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT07353931, a Phase 3 study of Osteoarthritis and Overweight or Obesity, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eloralintide
Study Locations (20)
California
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Wolverine Clinical Trials - Santa Ana
- Encompass Clinical Research - Spring Valley
- Diablo Clinical Research, Inc. - Walnut Creek
Arizona
- Care Access - 801 South Power Road, Mesa - Mesa
- Elite Pain and Spine Institute - South Crimson Road - Mesa
- Tucson Orthopaedic Institute - North Wyatt Drive - Tucson
Florida
- Westside Center for Clinical Research - Jacksonville
- Care Access - St. Petersburg - St. Petersburg
- Conquest Research - Winter Park
Massachusetts
- Skylight Health Research - Burlington - Burlington
- Care Access - Quincy - Quincy
New York
- Ellipsis Research Group - Brooklyn - 7th Street - Brooklyn
- Rochester Clinical Research - Buffalo - Buffalo
Alabama
- AMR Clinical - Mobile
Georgia
- Orita Clinical Research - Decatur
Illinois
- Great Lakes Clinical Trials - Ravenswood - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2028-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07353931
The ClinicalTrials.gov registry entry for NCT07353931 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 811-participant average among 135 other Osteoarthritis trials with a reported enrollment target (11% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07353931 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT07353931 about?
NCT07353931 is a clinical study titled "Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight". The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last abo...
What is the current status of trial NCT07353931?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2026-02-09. Estimated completion is 2028-05.
What conditions does trial NCT07353931 study?
This clinical trial studies the following conditions: Osteoarthritis, Overweight or Obesity.
What interventions are being tested in trial NCT07353931?
The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG).
Who is sponsoring clinical trial NCT07353931?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07353931 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Beat Pain Better Trial
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
RECRUITING · Phase 3
-
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
COMPLETED · Phase 3
-
Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe
COMPLETED · Phase 3
-
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
COMPLETED · Phase 3
-
Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.